

## DAFTAR PUSTAKA

1. Cvenkel B, S SS, Kirbis IS, Flezar MS. Symptoms and Signs of Ocular Surface Disease related to Topical Medication in Patients with Glaucoma. *Clin Ophthalmol* 2015;9:625-31.
2. Kahook MY, Lin S, Noecker RJ, Pflugfelder SC. Glaucoma Medications and Their Effects on The Corneal Surface. *Glaucoma Today*. 2007:1-13.
3. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of Ocular Symptoms and Signs with Preserved and Preservative Free Glaucoma Medication. *Br J Ophthalmol*. 2002;86:418-23.
4. Benitez-del-Castillo J, Cantu-Dibildox J, Galbis-Estrada C, Pinazo-Duran MD. Ocular Surface Morbidities in Glaucoma *European Ophthalmic Review* 2013;7(1):31-5.
5. Baudouin C. Ocular Surface Assesment of Glaucoma Drug Tolerance *Eur J Ophthalmol*. 2007;17(5):18-21.
6. Ilechie A, Abokyi S, Boateng G, Koffuor GA. Effect of Preserved and Preservative-free Timolol Eye Drops on Tear Film Stability in Healthy Africans *Niger Med J*. 2016;57(2):104-9.
7. Benitez-del-Castillo JM, Lemp MA. *Dry Eye Disease and Glaucoma. Ocular Surface Disorders* London: JP Medical Publishers; 2013.
8. Ramli N, Supramaniam G, Samsudin A, Juana A, Zahari M, Choo MM. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives. *American Academy of Optometry*. 2015;92:1-5.
9. Russ HH, Nogueira-Filho PA, Barros JdN, Faria NVLd, Montiani-Ferreira F. Ocular Surface Evaluation in Patients Treated with A Fix Combination of Prostaglandin Analogues with 0,5 % Timolol Maleat Topical Monotherapy: A Randomized Clinical Trial. *Clinics*. 2013;68(10):1318-24
10. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the Effects of Topical Levobunolol and Timolol Solution on the Human Ocular Surface. *Clinical Science*. 2003;22:709-15.
11. Turaçlı E, Budak K, Kaur A, Mizrak B, Ekinçi C. The effects of long-term topical glaucoma medication on conjunctival impression cytology. *International Ophthalmology*. 1997;21 (1):27-33
12. Verde JE. Effects Of Topical Timolol And Latanoprost By Tear Film Evaluation And Impression Cytology *Journal of Ophthalmic & Eye Research*. 2016;1(1):1-12.
13. Kovacevic S, Canovic S, Pacivic AD, Kolega MS, Basic JK. Ocular Surface Changes in Glaucoma Patients Related to Topical Medications. *Coll Antropol*. 2015;1:47-9
14. Baffa LdP, Ricardo JRdS, Dias AC, Modulo CM, Braz AM. Tear Film and Ocular Surface Alteration in Chronic Users of Antiglaucoma Medications. *Arq Bras Oftalmol*. 2008;71(1):1-8.
15. Radenkovic M, Stankovic-Babic G, Jovanovic P, Djordjevic-jocic J, Trenkic-Bozinovic M. Ocular Surface Disease Incidence in Patients with Open-Angle Glaucoma. *Srp Arh Oelok Lek*. 2016;144(7-8):376-83.
16. Cantor LB, Rapuano CJ, Cioffi GA. *Clinical Approach to Ocular Surface Disorders. External Disease and Cornea Basic and Clinical Science Course*

- Section 8. San Fransisco: American Academy of Ophthalmology; 2014-2015. p. 37-81
17. Barabino S, Dana MR. Dry Eye Syndromes. Immune Response and the Eye. *Chem Immunol Allergy*. 2007;92:176-84.
  18. B V, Himamshu, Sundeep, Nivedhita, Patil P, Liji, et al. Prevalence of Ocular Surface Disease in Glaucoma Patients Using Antiglaucoma Medications. *JEMDS*. 2013;2(24):4308-14
  19. Khamar MB, Danayak P, Shah R. Prevalence of Ocular Surface Disorder and Its Effect on Quality of Life in Patients with Glaucoma Using Topical Antiglaucoma Medications *Jcor*. 2017:1-6.
  20. Reynold AC. Topical Glaucoma Treatment and The Cornea. *Eyetubenet*. 2014::1-2.
  21. O'Dell LE. Using the SPEED Questionnaire to Identify Dry Eye. *Optometry Times*. 2015:1-6.
  22. Purslow. Modern Dry Eye Assessment- The Routine London SECO/AOP. 2013:1-13.
  23. Saade CE, Lari HB, Berezina TL, Fechtner RD. Topical Glaucoma Therapy and Ocular Surface Disease: A Prospective, Controlled Cohort Study. *Canadian Ophthalmology Society*. 2014:1-4.
  24. Masmali AM, Purslow C, Murphy PJ. The tear ferning test: a simple clinical technique to evaluate the ocular tear film. *Clin Exp Optom*. 2014;97:399-406.
  25. Feder RS, McLeod SD, Akpek EK, Dunn SP, Garcia-Ferrer FJ. Preferred Practice Pattern Dry Eye Syndrome. *American Academy of Ophthalmology*. 2013:1-32.
  26. Valente C, Iester M. Effects on the Ocular Surface Induced by Glaucoma Medication. *Expert Rev Ophthalmol*. 2010;5(3):405-12.
  27. Garoli E, Canton V, Magnani F, Nicodemo A, Viola F, Villani E. The Ocular Surface in Medically Controlled Glaucoma: an In Vivo Confocal Study *The Association for research in Vision and Ophthalmology*. 2014;55(13):1-3.
  28. Actis AG, Rolle T. Ocular Surface Alteration and Topical Antiglaucomatous Therapy: A Review *PMCID*. 2014:1-12.
  29. Chaglasian M. Glaucoma Management and Ocular Surface Disease. *Illinois Eye Institute*. 2015:1-13.
  30. Tsubota K, Tseng SCG, Nordlund ML. Anatomy and Physiology of the Ocular Surface. *Ocular Surface Disease: Medical and Surgical Management*. New York: Springer International Publishing AG; 2017. p. 3-15
  31. Zhang X, M VZ, Qu Y, He X, Ou S. Dry Eye Management: Targeting the Ocular Surface Microenvironment. *Int J Mol Sci*. 2017;18(7):1398.
  32. Cantor LB, Rapuano CJ, Cioffi GA. Structure and Function of the External Eye and Cornea External Disease and Cornea Basic and Clinical Science Course Section 8 San Fransisco: American Academy of Ophthalmology; 2014-2015. p. 3-10.
  33. Cantor LB, Rapuano CJ, Cioffi GA. Tear Film. *Fundamental and Principles of Ophthalmology Section 2*. San Francisco: American Academy of Ophthalmology; 2014-2015. p. 213-22.
  34. Foster CS, Azar DT, Dohlman CH. Keratokonjunctivitis Sicca: Physiology and Biochemistry of The Tear Film. *Smolin and Thoft's The Cornea Scientific*

- Foundations and Clinical Practice Fourth ed. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 577-601.
35. Levin LA, Albert DM. The Lacrimal Gland and Dry-Eye Disease Ocular Disease: Mechanisms and Management Madison: Saunders Elsevier; 2010. p. 105-13
  36. Cantor LB, Rapuano CJ, Cioffi GA. Medical Management of Glaucoma. Glaucoma Section 10. San Francisco: American Academy of Ophthalmology; 2014-2015. p. 159-77
  37. Baudouin C, Renard J-P, Nordmann J-P, Denis P, Lachkar Y. Prevalence and Risk Factor for Ocular Surface Disease Among Patients Treated Over The Long Term for Glaucoma or Ocular Hypertension. *Eur J Ophthalmol.* 2013;23(1):1-137.
  38. Society EG. European Glaucoma Society Terminology and Guidelines for Glaucoma. 4th Edition - Chapter 3: Treatment principles and options. *bjophthalmol.* 2016:1-72.
  39. Gross RL. The Evolution of Topical Therapy for Glaucoma. *Glaucoma Today Glaucoma and The Ocular Surface.* 2008:7-10.
  40. Ichpujani P, Ramasubramanian A. Ocular Surface Changes with Long-Term Topical Antiglaucoma Medications. *Journal of Current Glaucoma Practice.* 2009;3(3):19-26.
  41. Azuara-Blanco A, Costa VP, Wilson RP. Medical Therapy Handbook of Glaucoma. UK: Martin Dunitz; 2002. p. 161-80
  42. Rosin LM, Bell NP. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. *Clin Ophthalmol.* 2013;7:2131-5.
  43. Vasile P. Ocular Surface - A Complex and Vulnerable Adoptive Environment for Topical Glaucoma Treatment. *Romanian Journal of Ophthalmology.* 2016;60(3):153-7.
  44. Radhakrishnan S. Glaucoma Medications and Their Side Effect. 2016:1-6.
  45. Zimmerman TJ, Kooner KS. Principles and Complications of Medical Therapy of Glaucoma. *Clinical Pathway In Glaucoma.* New York: Thieme; 2001. p. 427-56
  46. Furtado JM, Paula JS, Soares EG, Dhegaide NHS, Rocha EM, Donadi E, et al. Conjunctival inflammation in patients under topical glaucoma treatment with indication to surgery. *Acta CirBras.* 2012;27(10):732-5.
  47. Ramesh K, Kaur I, Kaur P. Effect of Topical Antiglaucoma Drugs on Tear Film in Human Eyes. *IOSR-JDMS.* 2015;14(10).
  48. Whitson JT, Varner DL, Grove D, Netland PA. Glaucoma Drugs and The Ocular Surface. *Review of Ophthalmology.* 2006.
  49. Tsubota K, Yokoi N, Shimazaki J, Watanabe H, Dogru M, Yamada M. New Perspective on Dry Eye Definition and Diagnosis: A Consensus Report by the Asia Dry Eye Society. *The Ocular Surface.* 2017;15(1):65-76.
  50. Sharma A, Hindman HB. Aging: A Predisposition to Dry Eyes. *Hindawi Publishing Corporation Journal of Ophthalmology.* 2014;2014:1-8.
  51. Hauser W. From 2016: Take Care of The Ocular Surface in Glaucoma. *Advanced Ocular Care.* 2016:1-4.
  52. Lemp MA, Foulks GN. The Definition & Classification of Dry Eye Disease. *The Ocular Surface.* 2008:1-6.

53. Mathew NR, Bhandary SV, Rao KA, Handa D, Reddy RM. Meibography, A Recent Advancement In Dry Eye Evaluation. . All India Ophthalmological Society Proceeding. 2017:1-14.
54. Bowling B. Dry Eye. Kanski's Clinical Ophthalmology A Systematic Approach Eighth Edition. Philadelphia: Butterworth Heinemann Elsevier; 2016. p. 119-27
55. Singh R, Joseph A, Umapathy T, Tint NL, Dua HS. Impression cytology of the ocular surface. Br J Ophthalmol 2005;89:1655–9.
56. Gillan W. Conjunctival Impression Cytology: A Review S Afr Optom 2008;67(3):136-41
57. Wadani FAA, Nambiar R, Wahhab KMA, Asbali TA, Nambiar A, Rahaman AU. Reliability and Utility of Impression Cytology in the Diagnosis of Dry Eye. Nigerian Journal of Ophthalmology 2016;24(2):6-51.
58. Singh IP. Managing Ocular Surface Disease in Patients with Glaucoma. Ophthalmology Times. 2016;1-5.
59. Rashid W, Rather S, Singh T. Profile of Patients of Glaucoms in Kashmir Valley (A Hospital Based Study). JK Science. 2010;12(3):137-139
60. Skuta GL, Cantor LB, Weiss JS. Open Angle Glaucoma. Glaucoma, Section 10. San Francisco: American Academy of Ophthalmology. 2014-2015. p. 73-103
61. Quigley AH et al. The Prevalence of Glaucoma in a Population –Based Study of Hispanic Subject: Proyecto VER. Arc Ophthalmol. 2001;111:1819-1826
62. Kurna SA et al. The Effects of Topical Antiglaucoma Drugs as Monotherapy on the Ocular Surface: A Prospective Study. Journal of Ophthalmology. 2014:1-7
63. Vujkovic V, Mikac G, Kozomara R. Distribution and Density of Conjunctival Goblet Cells. Med Pregl. 2002;5-6:195-200
64. Zhu W et al. Age-Related Changes of Human Conjunctiva on in vivo confocal microscopy. Br J Ophthalmol. 2010;94:1448-1453
65. Pisella PJ et al. Conjunctival Proinflammatory and Proapoptotic Effects of Latanoprost and Preserved and Unpreserved Timolol: An Ex Vivo and In Vitro Study. IOVS. 2004;45(5): 1360-1368
66. Iyer JV et al. Ocular Lubricant Use in Medically and Surgically Treated Glaucoma: A Retrospective Longitudinal Analysis. Clinical Ophthalmology. 2017;11:1191-1196